New EU Filings Include First Self-Administered Treatment For Myasthenia Gravis
Executive Summary
UCB’s zilucoplan for treating gMG is among the latest new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.
You may also be interested in...
New EU Filings
Sugemalimab, from CStone Pharmaceuticals/EQRx, for use in combination with chemotherapy as first-line treatment for metastatic non-small cell lung cancer, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Aprocitentan, Idorsia/Janssen Biotech’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with resistant hypertension, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.